Agreement with Recursion Pharmaceuticals
Source: RNS
For immediate release |
19 September 2024 |
|
|
ANGLE plc ("the Company")
AGREEMENT WITH RECURSION PHARMACEUTICALS
New pharma agreement for Parsortix CTC analysis
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has signed an agreement with Recursion Pharmaceuticals, Inc. ("Recursion"), a leading clinical stage TechBio company decoding biology to radically improve lives.
The agreement is being initiated with a fully funded pilot study. Further details of the agreement are confidential between the parties.
ANGLE Chief Executive, Andrew Newland, commented:
"Whilst the study is modest in size during the pilot phase, there is the potential for larger follow-on contracts in the event of a successful pilot study. Recursion has partnerships with multiple leading large pharma companies and this agreement, ANGLE's fourth for 2024, further builds on the expansion of our large pharma services business."
For further information:
ANGLE plc |
+44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
|
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser |
+44 (0) 20 3207 7800 |
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) |
+44 (0) 203 727 1000 +1 (212) 850 5624 |
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.